82989-25-1
基本信息
他扎司特
化合物 T17001
丁基-3'-(1H-四唑-5-基)苯酰羧酸
TO-188
Tazanol
Tazalest
TAZANOLAST
Tazanolast(Tazalest,TO 188,WP 833)
Butyl 3'-(1H-tetrazol-5-y1)oxanilate
butyl 2-oxo-2-[3-(2H-tetrazol-5-yl)anilino]acetate
N-[3-(1H-Tetrazol-5-yl)phenyl]oxamidic acid butyl ester
Butyl 2-((3-(1H-tetrazol-5-yl)phenyl)aMino)-2-oxoacetate
物理化學(xué)性質(zhì)
常見問題列表
Tazanolast, an orally active mast-cell-stabilizing drug, which has been shown to suppress passive cutaneous anaphylaxis, Schultz-Dale reaction in isolated tracheal muscle, and experimental asthma without antagonistic actions upon histamine- and leukotriene-D4-induced contraction, IgE-mediated or compound 48/80-induced histamine release from mast cells and lung fragments, compound 48/80-induced Ca 2+ uptake into mast cells from extracellular medium, compound 48/80-induced translocation of protein kinase C from the cytosol to the membrane fraction of mast cells, and inositol trisphosphate production without directly inhibiting phospholipase C in mast cells.
Tazanolast administered before ozone exposure at doses of 30, 100, or 300 mg/kg inhibits ozone-induced airway hyperresponsiveness in a dose-dependent manner. Tazanolast administered after ozone exposure does not inhibit the airway hyperresponsiveness. Tazanolast does not significantly change the cell distribution of bronchoalveolar lavage (BAL) cells at 2 h after the exposure. Tazanolast significantly inhibits ozone-induced airway hyperresponsiveness in guinea pigs.